Searchable abstracts of presentations at key conferences in endocrinology

ea0090p147 | Pituitary and Neuroendocrinology | ECE2023

Baseline clinical and treatment characteristics of dopamine agonist treated patients in a Dutch national cohort of patients with prolactinoma

Zandbergen Ingrid , Pelsma Iris , van Furth Wouter , Biermasz Nienke

Introduction: Dopamine agonists (DA) are first-line treatment for prolactinomas and effectively control hyperprolactinemia in most patients. However, side effects may negatively impact health-related quality of life; and post-withdrawal remission rates are low, resulting in prolonged DA treatment.Methods: Dutch multicenter prospective observational cohort study mapping standard care for 316 prolactinoma patients. Baseline clinical characteristics and tre...

ea0063p1039 | Interdisciplinary Endocrinology 2 | ECE2019

The role of the growth hormone – insulin-like growth factor 1 axis in primary osteoarthritis

Pelsma Iris , Claessen Kim , Ramos Yolande , Meulenbelt Ingrid , Biermasz Nienke

Introduction: Increased insulin-like growth factor 1 (IGF-1) levels in patients with acromegaly are associated with clinical and radiological osteoarthritis (OA). We aimed to elucidate whether serum IGF-1 levels differ in patients with primary OA as compared to healthy controls and whether genetic variants known to affect serum IGF-1 levels are also associated with primary OA.Methods: Patients from the GARP study with familial generalized OA (n=...

ea0070aep215 | Bone and Calcium | ECE2020

Progression of vertebral fractures in long-term controlled acromegaly: A 9-year follow-up study

Pelsma Iris , Claessen Kim , Pereira Alberto , van Furth Wouter , Appelman-Dijkstra Natasha , Kloppenburg Margreet , Kroon Herman , Biermasz Nienke

Objective: Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess results in both reversible and irreversible damage to the skeleton, and includes increased vertebral fracture (VF) risk in the presence of normal BMD. The prevalence of VFs is approximately 60% in controlled acromegaly patients, and these VFs can progress during short-term follow-up. We aimed to identify the course of VFs and their associated risk factors in a cohort of acromegaly patients in long-t...